Type II diabetes mellitus
Clinical research at Kantonsspital Baden AG includes studies in type II diabetes mellitus, with attention to patients whose glycaemic control remains insufficient despite standard antidiabetic treatment. The sponsor’s work in this area reflects a focus on improving metabolic control and reducing the burden of diabetes-related complications.
- HbA1c reduction
- Anti-diabetic therapy
- Diabetes-related complications
The diabetes portfolio is centred on therapeutic strategies that support better long-term blood glucose management in adult patients.
Inflammatory and autoimmune disorders
The sponsor also funds research in inflammatory and autoimmune disorders, with clinical interest in treatment approaches for patients receiving systemic anti-inflammatory therapy. This area includes evaluation of treatment adjustment strategies in disorders where immune-mediated inflammation is a major clinical concern.
- Systemic glucocorticoid treatment
- Inflammatory disorders
- Autoimmune disease management
Research in this field is directed toward optimising care for conditions requiring careful control of immune-mediated inflammation.
Glucocorticoid therapy management
Another therapeutic domain of interest is the management of glucocorticoid treatment in patients with inflammatory conditions. The sponsor’s clinical activity includes questions around treatment discontinuation and tapering strategies, with relevance to routine care in steroid-treated patients.
- Systemic corticosteroids
- Treatment tapering
- Therapy discontinuation
This area links endocrine and immunological considerations in the management of chronic inflammatory disease.
